BIOMAT Database Logo BIOMAT Database Logo

Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis. 2020

Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Department of Infection Biology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.

Chitosan nanoparticles have gained attention as drug delivery systems (DDS) in the medical field as they are both biodegradable and biocompatible with reported antimicrobial and anti-leishmanial activities. We investigated the application of chitosan nanoparticles as a DDS for the treatment of cutaneous leishmaniasis (CL) by preparing two types of chitosan nanoparticles: positively charged with tripolyphosphate sodium (TPP) and negatively charged with dextran sulphate. Amphotericin B (AmB) was incorporated into these nanoparticles. Both types of AmB-loaded nanoparticles demonstrated in vitro activity against Leishmania major intracellular amastigotes, with similar activity to unencapsulated AmB, but with a significant lower toxicity to KB-cells and red blood cells. In murine models of CL caused by L. major, intravenous administration of AmB-loaded chitosan-TPP nanoparticles (Size = 69 ± 8 nm, Zeta potential = 25.5 ± 1 mV, 5 mg/kg/for 10 days on alternate days) showed a significantly higher efficacy than AmBisome® (10 mg/kg/for 10 days on alternate days) in terms of reduction of lesion size and parasite load (measured by both bioluminescence and qPCR). Poor drug permeation into and through mouse skin, using Franz diffusion cells, showed that AmB-loaded chitosan nanoparticles are not appropriate candidates for topical treatment of CL.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D010271 Parasites Invertebrate organisms that live on or in another organism (the host), and benefit at the expense of the other. Traditionally excluded from definition of parasites are pathogenic BACTERIA; FUNGI; VIRUSES; and PLANTS; though they may live parasitically. Parasite
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000287 Administration, Topical The application of drug preparations to the surfaces of the body, especially the skin (ADMINISTRATION, CUTANEOUS) or mucous membranes. This method of treatment is used to avoid systemic side effects when high doses are required at a localized area or as an alternative systemic administration route, to avoid hepatic processing for example. Drug Administration, Topical,Administration, Topical Drug,Topical Administration,Topical Drug Administration,Administrations, Topical,Administrations, Topical Drug,Drug Administrations, Topical,Topical Administrations,Topical Drug Administrations
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000981 Antiprotozoal Agents Substances that are destructive to protozoans. Schizonticides,Agents, Antiprotozoal
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.

Related Publications

Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Activity of liposomal amphotericin B against experimental cutaneous leishmaniasis.
April 1997, Antimicrobial agents and chemotherapy,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
February 2019, Drug delivery and translational research,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Chitosan-assisted immunotherapy for intervention of experimental leishmaniasis via amphotericin B-loaded solid lipid nanoparticles.
October 2014, Applied biochemistry and biotechnology,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B.
May 1984, Antimicrobial agents and chemotherapy,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Magnetic chitosan nanoparticles loaded with Amphotericin B: Synthesis, properties and potentiation of antifungal activity against common human pathogenic fungal strains.
December 2022, International journal of biological macromolecules,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Topical amphotericin B for cutaneous leishmaniasis.
July 1999, Archives of dermatology,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Development of amphotericin B loaded nanoparticles.
September 1998, Bollettino chimico farmaceutico,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Combination therapy with tamoxifen and amphotericin B in experimental cutaneous leishmaniasis.
May 2014, Antimicrobial agents and chemotherapy,
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Antileishmanial Activity of Amphotericin B-loaded-PLGA Nanoparticles: An Overview.
July 2018, Materials (Basel, Switzerland),
Alaa Riezk, and Katrien Van Bocxlaer, and Vanessa Yardley, and Sudaxshina Murdan, and Simon L Croft
Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.
April 2021, Drug delivery and translational research,
Copied contents to your clipboard!